Mutagenized Lactobacillus acidophilus for gastrointestinal fat extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-obesity pharmaceuticals, such as sibutramine and Orlistat™, have significant side effects and are not ideal for treating obesity, as they either affect the brain or cause gastrointestinal issues, whereas manipulating gut microbiota to reduce dietary fat absorption offers a more effective and safer approach.
Innovation Solution
Mutagenized Lactobacillus acidophilus strains with enhanced fatty acid removal capabilities, known as FARM, are administered to colonize the gastrointestinal tract, reducing dietary fat absorption by actively extracting free fatty acids, thereby reducing caloric intake and body weight.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sibutramine is used to inhibit re-uptake of noradrenaline and serotonin, then appetite control is improved, but side effects on heart rate and blood pressure worsen
Solution Approach 1:
The patent introduces gut microbiota as an intermediary mediator between diet and host metabolism. By manipulating the microbial community in the gastrointestinal tract, the invention achieves weight loss and metabolic improvement without direct pharmacological action on the brain or cardiovascular system, thus avoiding the harmful side effects of sibutramine while maintaining appetite control benefits
Solution Approach 2:
The invention replaces the central nervous system mechanism (brain-based appetite suppression by sibutramine) with a peripheral biological mechanism (gut microbiota-mediated fat absorption reduction). This substitution shifts the site of action from the brain to the gastrointestinal tract, eliminating cardiovascular side effects while achieving similar weight management outcomes
2Reliability
If Orlistat is used to inhibit fat hydrolysis, then dietary fat absorption is reduced, but undigested fat causes gastrointestinal side effects
Solution Approach 1:
The patent extracts and isolates specific bacterial strains from the gut microbiota that possess enhanced lipolytic activity. These selected bacteria are then administered to selectively remove fatty acids from dietary fats in the gastrointestinal tract, achieving fat absorption reduction without the uncontrolled hydrolysis and undigested fat accumulation caused by Orlistat
Solution Approach 2:
The invention changes the biochemical parameters of the gut microbiota by introducing strains with modified lipolytic enzyme activities. This parameter change enables controlled fat breakdown and absorption reduction, avoiding the excessive hydrolysis that leads to gastrointestinal side effects with conventional drugs like Orlistat
3Weight of moving object
If gut microbiota is manipulated to reduce caloric extraction, then body weight reduction is achieved, but the mechanism of action requires further clarification
Solution Approach 1:
The patent employs self-service principles by using the gut microbiota's natural metabolic functions to achieve weight loss. The introduced bacterial strains autonomously perform fat hydrolysis and short-chain fatty acid production, eliminating the need for complex external monitoring or adjustment mechanisms and simplifying the overall treatment approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
FARM strains demonstrate weight loss and metabolic syndrome improvements comparable to Orlistat™, with superior safety and risk-benefit profiles by acting peripherally and avoiding gastrointestinal side effects, while maintaining beneficial probiotic properties.
Implementation Method 1
Lactobacillus acidophilus FARM strains with enhanced fatty acid removal capabilities are administered to colonize the gastrointestinal tract, reducing dietary fat absorption by actively extracting free fatty acids
Data Source
AI summary
The present invention relates to the prevention and treatment of obesity and obesity related metabolic syndrome, particularly to the prevention and treatment of obesity by changing intestinal flora. The characteristics of intestinal bacteria are transformed by administration of a microorganism preparation which improves free fatty acid absorption by the bacteria, and free fatty acid absorption in the gastrointestinal tract is thereby decreased by introduction thereof. The present invention provides a method for preventing and treating obesity and obesity related metabolic syndrome, a pharmaceutical composition and diet supplement for prevention and treatment thereof, and modified probiotic strains usable for such purposes. The present invention provides a weight loss effect and shows that the absorption of fatty acids in the gastrointestinal tract is blocked by improving the characteristics of intestinal bacteria and transplanting them, thereby enabling the treatment of obesity.